Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naive men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml^-1 to 10 ng ml^-1.

ABSTRACT: We attempted to perform risk categories based on the free/total prostate-specific antigen ratio (%fPSA), prostate-specific antigen (PSA) density (PSAD, in ng ml^-2), and multiparametric magnetic resonance imaging (mpMRI) step by step, with the goal of determining the best clinical diagnostic strategy to avoid unnecessary tests and prostate biopsy (PBx) in biopsy-naïve men with PSA levels ranging from 4 ng ml^-1 to 10 ng ml^-1. We included 439 patients who had mpMRI and PBx between August 2018 and July 2021 (West China Hospital, Chengdu, China). To detect clinically significant prostate cancer (csPCa) on PBx, receiver-operating characteristic (ROC) curves and their respective area under the curve were calculated. Based on %fPSA, PSAD, and Prostate Imaging-Repor

SUBMITTER: Zhang CC 

PROVIDER: S-EPMC10411252 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature